| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cellular retinoic acid-binding protein II; CRABP-II |
| Entrez GeneID | 1382 |
| WB Predicted band size | Calculated MW: 16 kDa; Observed MW: 16 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human CRABP2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于CRABP2抗体的3篇参考文献示例(注：文献信息为模拟概括，仅供参考)：
---
1. **文献名称**：CRABP2 as a Biomarker in Triple-Negative Breast Cancer
**作者**：Lee J, et al.
**摘要**：研究通过CRABP2抗体进行免疫组化分析，发现CRABP2在三阴性乳腺癌中显著高表达，并与肿瘤侵袭性和患者生存率下降相关。提示其可作为潜在治疗靶点。
2. **文献名称**：CRABP2-Mediated Retinoic Acid Signaling in Pancreatic Cancer
**作者**：Zhang Y, et al.
**摘要**：利用CRABP2抗体进行Western blot和免疫荧光实验，证实CRABP2通过调控视黄酸信号通路促进胰腺癌细胞增殖和转移，敲低CRABP2可抑制肿瘤生长。
3. **文献名称**：CRABP2 Expression Correlates with Chemotherapy Resistance in Ovarian Cancer
**作者**：Wang H, et al.
**摘要**：通过CRABP2抗体检测卵巢癌组织样本，发现高表达CRABP2的患者对铂类化疗耐药性更强，机制涉及DNA修复通路的异常激活。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“CRABP2 antibody”、“CRABP2 cancer expression”获取最新研究。
Cellular retinoic acid-binding protein 2 (CRABP2) is a small intracellular lipid-binding protein that facilitates the transport and metabolism of retinoic acid (RA), a derivative of vitamin A with critical roles in cellular differentiation, proliferation, and apoptosis. Unlike its homolog CRABP1. CRABP2 primarily shuttles RA to nuclear retinoic acid receptors (RARs), where RA-RAR complexes regulate the transcription of target genes involved in development and homeostasis. CRABP2 is expressed in various tissues, including skin, neurons, and certain cancers, where its dysregulation has been linked to pathological processes. Overexpression of CRABP2 is observed in multiple malignancies, such as breast, ovarian, and lung cancers, and is often associated with enhanced tumor aggressiveness, metastasis, and poor prognosis, potentially due to its role in modulating RA signaling or cross-talk with other oncogenic pathways.
Antibodies targeting CRABP2 are essential tools for studying its expression, localization, and function in both physiological and disease contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels in tissue samples or cell lines. Specificity validation via knockout controls or peptide blocking is critical, as CRABP2 shares structural homology with CRABP1. Research applications include investigating CRABP2's role in cancer progression, its interplay with retinoid-based therapies, and its potential as a diagnostic or prognostic biomarker. Recent studies also explore its involvement in non-cancer pathways, such as neural development and skin disorders.
×
